Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy

Leukemia & Lymphoma
I A Haagen

Abstract

Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on target cells and for surface markers on immune effector cells, have been shown (in vitro) to be effective in directing and triggering effector cells to kill target cells resulting in target cell lysis. Bispecific monoclonal antibodies (BsAb) against the CD3 antigen on T cells and the CD19 antigen on B cell were developed. Data obtained by in vitro experiments might indicate that clinical responses in BsAb immunotherapy, will only be obtained in patients with minimal tumor load, and may need additional T cell stimulation via cytokines such as IL-2. Although these experiments have shown us their limitations, they also include the promise of BsAb-directed immunotherapy in B cell malignancy as further demonstrated during a Phase I trail, showing little toxicity. Clearly, much remains to be done before this BsAb is routinely used for therapy, but, the results presented show that the CD3xCD19 BsAb has a potential as a therapeutic agent in B cell malignancy. This report describes the experiments performed to test a new immunotherapeutic approach for the treatment of B cell malignancy. Bispecific antibodies are described that can target cytotoxic...Continue Reading

References

Dec 1, 1992·European Journal of Immunology·M de BoerJ Reeder
Nov 1, 1991·Trends in Biotechnology·M W Fanger, P M Guyre
Aug 1, 1992·Immunobiology·D M SegalJ R Wunderlich
Dec 1, 1992·British Journal of Cancer·R FoaB Gansbacher
Jun 1, 1992·International Clinical Psychopharmacology·S A Montgomery
Jan 1, 1992·Journal of Photochemistry and Photobiology. B, Biology·M L JinP Ren
Jan 11, 1992·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·J R JacksonR B Raney
Jun 1, 1992·International Immunology·B BeverlyR H Schwartz
Oct 1, 1991·European Journal of Immunology·G JungW Wilmanns
Feb 1, 1991·Immunology Today·M W FangerJ L Romet-Lemonne
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·A HekmanC J Melief
Jun 1, 1991·European Journal of Immunology·A TuttM J Glennie
Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M VriesendorpS E Order
Apr 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P Siegel, R K Puri
Jun 1, 1990·Immunology Today·C H JuneC B Thompson
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P S LinsleyJ A Ledbetter
Apr 1, 1990·British Journal of Haematology·A J Veerman, R Pieters
Jun 1, 1990·Immunology Today·M T Lotze, O J Finn
Nov 8, 1985·Science·L J Old
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·F M Uckun, J A Ledbetter
Feb 1, 1989·Cellular Immunology·M A de RieF Miedema
Jan 1, 1989·Current Opinion in Immunology·P J Friend
Feb 1, 1989·European Journal of Immunology·M ClarkH Waldmann

❮ Previous
Next ❯

Citations

Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Torsten DreierPatrick A Baeuerle
May 14, 2005·Cancer Immunology, Immunotherapy : CII·An WillemsNico Mertens
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Tom van Meerten, Anton Hagenbeek
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSusan O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.